TCRX · TScan Therapeutics, Inc.
$0.77
+0.00 (+0.23%)
At close · Jul 28
Market Cap
$50.58M
Shares
65.35M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Gavin MacBeath | CEO | $2,801,450 |
| Chrystal Louis | Chief Medical Officer | $1,609,600 |
| Jason A. Amello | CFO | $1,275,995 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jason A. Amello | CFO | $3,733,892 |
| Chrystal Louis | Chief Medical Officer | $3,030,461 |
| Gavin MacBeath | CEO | $1,760,671 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Gavin MacBeath | CEO | $3,196,054 |
| Debora Barton | Chief Medical Officer | $1,709,996 |
| Brian Silver | CFO | $1,584,172 |
| Zoran Zdraveski | Chief Legal and Strategy Officer and Secretary | $1,581,766 |
| David Southwell | CEO | $1,292,446 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Southwell | CEO | $2,142,743 |
| Brian Silver | CFO | $1,601,123 |
| Gavin MacBeath | CEO | $1,361,727 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Brian Silver | CFO | $3,182,986 |
| David Southwell | CEO | $2,807,486 |
| Gavin MacBeath | CEO | $1,189,840 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David Southwell | CEO | $750,238 |